Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads heart scans to predict heart attacks

NCT ID NCT06025305

Diagnosis Sponsor: Jinling Hospital, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is developing an artificial intelligence system to analyze CT scans of the heart. The goal is to automatically detect and measure dangerous plaque that can cause heart attacks. Researchers will compare the AI's findings with detailed imaging tests and track patient outcomes in 2,000 participants across China.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI diagnostic software
What this could lead to
If successful, this AI could help doctors spot dangerous plaque earlier and better predict heart attacks, leading to more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. The AI may not perform as well in real-world settings, and results may not apply outside China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

consecutive patients who first underwent CCTA and then Intravascular imaging in China

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Intravascular imaging (including intravascular ultrasound or optical coherence tomography) was performed within 3 months after CCTA; * No change in medications or clinical symptoms during CCTA and intravascular imaging examinations; * Coronary artery diameter stenosis of 30% to 90% on invasive coronary imaging. Exclusion Criteria: * Image quality of CCTA or intravascular US was inadequate to analyze; * Intravascular imaging was performed after percutaneous coronary intervention (PCI) or pre-dilation of the target lesions; * Lesions could not be co-registered between CCTA and intravascular US; * Missing CCTA or intravascular US data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis coronary artery disorder Plaque, Atherosclerotic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Plaque, atherosclerotic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Institute Of Medical Imaging Jinling Hospital

    Nanjing, Jiangsu, 210018, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.